As an expert in the field of messenger ribonucleic acid (mRNA) studies, Creative Biolabs is helping our customers with various mRNA therapeutic services targeting regenerative medicine. Based on our deep analytical capabilities and vast experience in mRNA studies, our client-focused, integrated team will anticipate challenges, overcome difficulties, and provide custom mRNA-based preclinical studies with numerous assays. We guarantee the finest results for our customers all over the world.
Regenerative medicine is a branch of modern medicine that seeks to develop novel methods for replacing, repairing, or healing damaged cells, tissues, and organs. Pilot studies have shown that regenerative medicine has been widely used for treating a wide array of disease conditions, such as progressive disorders, diabetes, as well as arthritis. In general, regenerative medicine is composed of the design and application of stem cells, tissue engineering, immunomodulation therapy, cellular therapies, and the generation of medical devices or artificial organs. Among them, the delivery of therapeutic cells to specific tissues has become a common strategy for regenerative medicine. Till now, different kinds of autologous cells or allogeneic cells have been broadly used for further proliferating in target tissues or organs. Meanwhile, recent researchers have revealed that synthetic mRNAs play an important role in regulating the delivery of functional proteins in regenerative medicine.
Fig.1 Native mRNA structure. (Patel, 2019)1
Regenerative medicine has proven its significant role in regenerating the damaged cells or tissues. A panel of assays, such as tissue engineering and cell-based assays, have been generated for restoring the normal function of cells or tissues. Among them, proteins have been regarded as critical molecules that are essential to regulate cell growth, cell differentiation, cell proliferation, cell metabolism, and cell apoptosis. Many actions have been taken to help the effective delivery of these proteins into loss-of-function sites. However, direct injection of proteins has caused several issues reflecting their low in vivo stability and biological activities. As a consequence, recent studies have indicated that mRNAs are emerging as safe and promising alternatives for proteins that can be transported to the defect sites.
With the commitment of being your best mRNA therapeutics development partner, Creative Biolabs has established the utmost efficient integrated mRNA solutions to innovate and accelerate your development process for many applications, especially for regenerative medicine. Equipped with a team of professional scientists, we have generated a group of mRNA-based systems for our clients to offer mRNA design and synthesis, mRNA modification and purification, mRNA delivery, as well as mRNA-based stem cell engineering. For example, we have developed several efficient mRNA polymeric delivery systems that have been used for the treatment of pulmonary diseases. Besides, we also provide a range of mRNA-based therapeutics optimization services to improve the stability and transmission capacity and reduce the potential immunogenicity of mRNA in clinical use.
Fig.2 Structural features of different sugar and base modifications to enhance translational efficacy of mRNA with reduced immunogenicity. (Patel, 2019)2
Creative Biolabs is dedicated to expanding cutting edge mRNA research across a range of applications. With our proven competencies and regulatory expertise, we are therefore confident in offering the best mRNA services for regenerative medicine. We can provide many flexible options, from which you can always find a better match for your particular project. If you are interested in our services, please feel free to contact us for more information.
Inquire About Our ServicesA: mRNA-based regenerative medicine uses synthetic mRNA to promote the repair, replacement, or regeneration of damaged cells, tissues, or organs. This approach leverages mRNA to instruct cells to produce proteins that are essential for tissue regeneration, offering a safer and more efficient alternative to direct protein delivery.
A: mRNA facilitates tissue regeneration by encoding proteins that regulate vital processes such as cell growth, differentiation, and metabolism. These proteins help restore function to damaged tissues, making mRNA a key tool in regenerative medicine, particularly when direct protein delivery is impractical due to stability and activity issues.
A: The benefits include precise control over protein expression, reduced risk of immunogenicity, and the ability to target specific cells or tissues. mRNA can be designed to produce therapeutic proteins only when and where they are needed, leading to more effective and personalized regenerative therapies.
A: This approach can be used to treat a variety of conditions, including degenerative diseases, diabetes, and arthritis. It is also applicable in wound healing and the regeneration of heart, lung, and other vital tissues, where restoring normal function is critical.
A: Challenges include ensuring mRNA stability, avoiding degradation before reaching the target cells, and minimizing potential immune responses. Creative Biolabs addresses these through mRNA modifications and optimized delivery systems that enhance the efficacy and safety of the therapies.
A: Creative Biolabs provides a range of services, including mRNA design, synthesis, modification, and delivery system development. They also offer preclinical studies to evaluate the safety and effectiveness of mRNA-based therapies, supporting the development of new regenerative treatments.
Engineered insulin-like growth factor I (IGF-I) mRNA was evaluated for its regenerative therapeutic potential in muscle injuries and spinal disc herniation. The study utilized optimized IGF-I mRNA constructs with enhanced signal peptides to improve protein secretion. Experimental results demonstrated that local administration of this engineered mRNA significantly accelerated muscle regeneration in a mouse model of severe muscle injury. In a rabbit model of spinal disc herniation, the IGF-I mRNA treatment halted the progression of disc degeneration and improved disc height, showing substantial tissue repair. These findings suggest that engineered IGF-I mRNA has strong potential for regenerative therapeutics, offering a promising strategy for treating conditions like muscle injuries and spinal disc degeneration by promoting local tissue regeneration.
Fig.3 Evaluation of endogenous versus optimized IVT IGF-I mRNA in a mouse model of myotoxic injury.2
| Cat. No | Product Name | Promoter |
|---|---|---|
| GTVCR-WQ30MR | IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR, 11F8 Vector | SP6 |
| GTVCR-WQ31MR | IVTScrip™ pT7-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector | T7 |
| GTVCR-WQ34MR | IVTScrip™ pSP6-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector | SP6 |
| GTVCR-WQ36MR | IVTScrip™ pT7-VEE-mRNA-Anti-EGFR, 1-26/3-67 Vector | T7 |
| GTVCR-WQ38MR | IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR, 1-26/3-67 Vector | SP6 |
| Cat. No | Product Name | Type |
|---|---|---|
| GTTS-WQ20MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ21MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ22MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ23MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ24MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) | Antibody |
References
